There is one clinical trial.
Current clinical prediction scores for acute respiratory distress syndrome (ARDS) have limited positive predictive value. No studies have evaluated predictive kinetics of plasma biomarkers and receptor for advanced glycation end products (RAGE) polymorphisms in a broad population of critically ill patients or as an adjunct to clinical prediction scores. The main objective of the investigators study is to evaluate the predictive values of plasma soluble RAGE levels for the onset of ARDS in a high risk population of patients admitted to the intensive care unit (ICU). One of the investigators goals is to improve early identification of patients at risk for ARDS in order to better implement preventive stategies prior to ARDS development. The primary outcome is the occurrence of ARDS during the first week after admission to the ICU.
The secondary objectives are to : - to evaluate the predictive value of RAGE polymorphisms (_429 T/C, _374 T/A, 2184 A/G, Gly82Ser) for the onset of ARDS - to evaluate the predictive value of maximal plasma levels of RAGE soluble forms for the onset of ARDS - to test the relationship between RAGE polymorphisms and plasma sRAGE and esRAGE levels - to test whether serial sRAGE measurements would improve the discrimination of the LIP Score or not - to evaluate the prognostic value of plasma levels of RAGE soluble forms for : duration of mechanical ventilation, length of stay in the ICU and 30-day mortality. --- Gly82Ser ---
Description: The development of ARDS, based on Berlin definition criteria, during the first week after admission to the ICUMeasure: development of ARDS Time: during the first week after admission to the ICU